insights_auto
Kodėl „4142“ sumažėjo 6,62%?
Įsigilintichevron_right
4142:TPE
Adimmune Corp
14,80 TWD
arrow_downward
−6,62%(−1,05) 1 D.
11-20, 13:30:09 GMT+8 · TWD
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „4142“ įžvalgos...
Atidaryti
15,75 TWD
Aukšta
15,75 TWD
Žema
14,80 TWD
Rinkos kapitalizacija
6,36 mlrd.
Vid. kiekis
1,13 mln.
Apimtis
1,63 mln.
P/E santykis
85,76
52 sav. aukšta
21,50 TWD
52 sav. žema
14,80 TWD
Pajamos iš vienos akcijos
0,17 TWD
Neapmokėtos akcijos
235,29 mln.
Darbuotojų skaičius
564
Atidaryti
15,75 TWD
Aukšta
15,75 TWD
Žema
14,80 TWD
Rinkos kapitalizacija
6,36 mlrd.
Vid. kiekis
1,13 mln.
Apimtis
1,63 mln.
P/E santykis
85,76
52 sav. aukšta
21,50 TWD
52 sav. žema
14,80 TWD
Pajamos iš vienos akcijos
0,17 TWD
Neapmokėtos akcijos
235,29 mln.
Darbuotojų skaičius
564
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
The Motley Fool
·
prieš 55 minutes
In the Last Tech Bust, the S&P 500 Lost Money for a Decade. History Says Stocks With the Highest Yields Gained 5.4% a Year.
Yahoo Finance
·
prieš 4 valandas
T-Bills Are Beating the Nasdaq, S&P 500 and Dow This Year
Benzinga
·
prieš 2 valandas
S&P 500 Has Slumped Into a Correction as Goldman Sachs Panic Index Points to More Downside
Beinsure
·
prieš 5 valandas
Vanguard S&P 500 ETF: How investing in VOO could build a $1 mn portfolio
Profilis
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Apie „Adimmune Corp“
Generalinis direktorius-
Darbuotojai564
Įkurta1965
Pagrindinė būstinė-
SektoriusHealth Care
Pramonės sritis-
Svetainėadimmune.com.tw